Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Seres Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Seres Therapeutics, Inc.

MCRB

Seres Therapeutics, Inc.

About Seres Therapeutics, Inc.

Seres Therapeutics is a biopharmaceutical company specializing in live biotherapeutics to treat serious medical conditions. Its core focus is developing oral microbial therapies to prevent infections, improve immune regulation, and address inflammatory diseases. The company’s pipeline includes investigational products targeting bacterial bloodstream infections, gastrointestinal pathogens, and inflammatory bowel disease, leveraging proprietary microbiome platforms for drug discovery, manufacturing, and regulatory success.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Seres Therapeutics, Inc.

1
1
Seres Therapeutics, Inc. Seres Therapeutics Reports $19.9 Million Net Loss in Q1 2026 Amid Workforce Reduction

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Seres Therapeutics, Inc. Seres Therapeutics Reports $5.7M Net Income for 2025, Significant Recovery from Previous Year

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Seres Therapeutics, Inc. Seres Therapeutics Reports Q3 2025 Financial Results with Revenue of $351,000 and Net Income of $8.2 Million

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Seres Therapeutics, Inc. Seres Therapeutics Reports $12.8M Net Income and Strategic Focus on SER-155

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Seres Therapeutics, Inc. Seres Therapeutics Reports $32.7 Million Net Income and Strategic Focus on SER-155

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Seres Therapeutics, Inc. Seres Therapeutics Reports $125.7M Net Loss for 2024, Sells VOWST Business for $234.2M

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Seres Therapeutics, Inc. Seres Therapeutics Reports Significant Financial Developments, Including $139.8M Net Income from Discontinued Operations in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments